| Ibrutinib and venetoclax for first-line treatment of CLL N Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ... New England Journal of Medicine 380 (22), 2095-2103, 2019 | 487 | 2019 |
| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study E Jabbour, H Kantarjian, F Ravandi, D Thomas, X Huang, S Faderl, ... The Lancet Oncology 16 (15), 1547-1555, 2015 | 299 | 2015 |
| Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials K Sasaki, SS Strom, S O'Brien, E Jabbour, F Ravandi, M Konopleva, ... The Lancet Haematology 2 (5), e186-e193, 2015 | 292 | 2015 |
| 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ... The Lancet Haematology 7 (10), e724-e736, 2020 | 242 | 2020 |
| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single … E Jabbour, NJ Short, F Ravandi, X Huang, N Daver, CD DiNardo, ... The Lancet Haematology 5 (12), e618-e627, 2018 | 223 | 2018 |
| Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia NJ Short, E Jabbour, K Sasaki, K Patel, SM O’Brien, JE Cortes, R Garris, ... Blood, The Journal of the American Society of Hematology 128 (4), 504-507, 2016 | 220 | 2016 |
| Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase … H Kantarjian, F Ravandi, NJ Short, X Huang, N Jain, K Sasaki, N Daver, ... The Lancet Oncology 19 (2), 240-248, 2018 | 215 | 2018 |
| Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, L Xiao, T Kadia, ... Journal of Clinical Oncology 39 (25), 2768-2778, 2021 | 207 | 2021 |
| A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs D Rea, MJ Mauro, C Boquimpani, Y Minami, E Lomaia, S Voloshin, ... Blood, The Journal of the American Society of Hematology 138 (21), 2031-2041, 2021 | 198 | 2021 |
| Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia K Morita, HM Kantarjian, F Wang, Y Yan, C Bueso-Ramos, K Sasaki, ... Journal of Clinical Oncology 36 (18), 1788, 2018 | 181 | 2018 |
| Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN E Jabbour, NJ Short, G Montalban-Bravo, X Huang, C Bueso-Ramos, ... Blood, The Journal of the American Society of Hematology 130 (13), 1514-1522, 2017 | 177 | 2017 |
| Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: a propensity … K Sasaki, EJ Jabbour, F Ravandi, NJ Short, DA Thomas, ... Cancer 122 (23), 3650-3656, 2016 | 176 | 2016 |
| Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors P Jain, H Kantarjian, KP Patel, GN Gonzalez, R Luthra, RK Shamanna, ... Blood, The Journal of the American Society of Hematology 127 (10), 1269-1275, 2016 | 172 | 2016 |
| Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients P Jain, HM Kantarjian, A Ghorab, K Sasaki, EJ Jabbour, ... Cancer 123 (22), 4391-4402, 2017 | 147 | 2017 |
| Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic … E Jabbour, F Ravandi, P Kebriaei, X Huang, NJ Short, D Thomas, ... JAMA oncology 4 (2), 230-234, 2018 | 140 | 2018 |
| Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens CA Lachowiez, S Loghavi, TM Kadia, N Daver, G Borthakur, ... Blood advances 4 (7), 1311-1320, 2020 | 130 | 2020 |
| Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes GN Tamamyan, HM Kantarjian, J Ning, P Jain, K Sasaki, KL McClain, ... Cancer 122 (18), 2857-2866, 2016 | 122 | 2016 |
| Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs P Jain, H Kantarjian, PC Boddu, GM Nogueras-González, S Verstovsek, ... Blood advances 3 (6), 851-861, 2019 | 109 | 2019 |
| De novo acute myeloid leukemia: a population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017 K Sasaki, F Ravandi, TM Kadia, CD DiNardo, NJ Short, G Borthakur, ... Cancer 127 (12), 2049-2061, 2021 | 103 | 2021 |
| Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens A Maiti, CR Rausch, JE Cortes, N Pemmaraju, NG Daver, F Ravandi, ... Haematologica 106 (3), 894, 2021 | 101 | 2021 |
Guillermo Garcia-ManeroMD Anderson Cancer CenterVerified email at mdanderson.org
